IgA nephropathy
Conditions
Brief summary
Quantitative reduction of proteinuria and haematuria (based on 24-hr urine collection(s)) from baseline to Week 26 (6 months after starting treatment with ravulizumab)
Detailed description
Percentage of participants achieving complete remission 26 weeks after treatment with ravulizumab, Evolution of proteinuria and haematuria (based on 24- hr urine collection(s)) after treatment withdrawal (from Week 26 to Week 46), To measure the evolution of serum creatinine levels (quantitative) from baseline to Week 46, To measure the evolution of urine C5b-9 levels (quantitative) from baseline to Week 46, To measure the slope of eGFR computed from baseline to Week 46, Proportion of patients discontinuing treatment with ravulizumab due to adverse effects associated with the drug
Interventions
Sponsors
Institut De Recerca Biomedica De Lleida Fundacio Dr. Pifarre, Institut De Recerca Biomedica De Lleida Fundacio Dr. Pifarre
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Quantitative reduction of proteinuria and haematuria (based on 24-hr urine collection(s)) from baseline to Week 26 (6 months after starting treatment with ravulizumab) | — |
Secondary
| Measure | Time frame |
|---|---|
| Percentage of participants achieving complete remission 26 weeks after treatment with ravulizumab, Evolution of proteinuria and haematuria (based on 24- hr urine collection(s)) after treatment withdrawal (from Week 26 to Week 46), To measure the evolution of serum creatinine levels (quantitative) from baseline to Week 46, To measure the evolution of urine C5b-9 levels (quantitative) from baseline to Week 46, To measure the slope of eGFR computed from baseline to Week 46, Proportion of patients discontinuing treatment with ravulizumab due to adverse effects associated with the drug | — |
Countries
Spain
Outcome results
None listed